Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edna Mozes

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Immunotherapy|July 20, 2010
Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseasesAmir Sharabi, Edna Mozes
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2008
The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cellsAmir Sharabi, Edna Mozes
Autoimmunity Reviews|July 28, 2010
A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosusEdna Mozes, Amir Sharabi
Arthritis Research & Therapy|August 7, 2010
Bcl-xL affects the development of functional CD4 TregsAmir Sharabi, Edna Mozes
Proceedings of the National Academy of Sciences of the United States of America|August 17, 2004
Therapeutic vaccines in autoimmunityMichael Sela, Edna Mozes
Autoimmunity|October 23, 2002
Treatment of induced murine SLE with a peptide based on the CDR3 of an anti-DNA antibody reverses the pattern of pathogenic cytokinesNaama Brosh, Heidy Zinger, Edna Mozes
The Israel Medical Association Journal : IMAJ|February 28, 2008
A novel synthetic peptide for the specific treatment of lupus: clinical effects and mechanism of actionEdna Mozes, Uri Sela, Amir Sharabi
Journal of Autoimmunity|July 15, 2009
Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptideAmir Sharabi, Smadar Lapter, Edna Mozes
Journal of Autoimmunity|June 25, 2014
Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosusZev Sthoeger, Amir Sharabi, Edna Mozes
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2005
Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosisHava Ben-David, Michael Sela, Edna Mozes
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Immunotherapy|July 20, 2010
Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseasesAmir Sharabi, Edna Mozes
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2008
The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cellsAmir Sharabi, Edna Mozes
Autoimmunity Reviews|July 28, 2010
A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosusEdna Mozes, Amir Sharabi
Arthritis Research & Therapy|August 7, 2010
Bcl-xL affects the development of functional CD4 TregsAmir Sharabi, Edna Mozes
Proceedings of the National Academy of Sciences of the United States of America|August 17, 2004
Therapeutic vaccines in autoimmunityMichael Sela, Edna Mozes
Autoimmunity|October 23, 2002
Treatment of induced murine SLE with a peptide based on the CDR3 of an anti-DNA antibody reverses the pattern of pathogenic cytokinesNaama Brosh, Heidy Zinger, Edna Mozes
The Israel Medical Association Journal : IMAJ|February 28, 2008
A novel synthetic peptide for the specific treatment of lupus: clinical effects and mechanism of actionEdna Mozes, Uri Sela, Amir Sharabi
Journal of Autoimmunity|July 15, 2009
Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptideAmir Sharabi, Smadar Lapter, Edna Mozes
Journal of Autoimmunity|June 25, 2014
Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosusZev Sthoeger, Amir Sharabi, Edna Mozes
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2005
Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosisHava Ben-David, Michael Sela, Edna Mozes
Pageof 6